Log in to your Inderes Free account to see all free content on this page.

Saniona

21.50 SEK

+4.88 %

Less than 1K followers

SANION

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+4.88 %

+32.06 %

+78.87 %

+118.05 %

+167.41 %

+167.08 %

+740.00 %

+15.50 %

+448.98 %

Saniona is a biotechnology company focused on developing innovative treatments for neurological and psychiatric diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Saniona was founded in 2011 and is headquartered in Denmark.

Market cap

2.97B SEK

Turnover

17.52M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

26.2.

2026

Annual report '25

27.5.

2026

General meeting '26

27.5.

2026

Interim report Q1'26

All

Research

Press releases

ShowingAll content types

Press release12/17/2025, 7:00 AM

Saniona Bolsters Leadership Team to Accelerate Development of Key CNS Programs

Press release12/1/2025, 12:21 PM

BioStock: Saniona comments on major advancements during third quarter

Press release11/28/2025, 10:44 AM

Redeye: Saniona (Q3 Review) - Gearing up for clinical development

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/27/2025, 7:00 AM

Saniona publishes its interim report for the third quarter of 2025

Press release11/20/2025, 7:00 AM

Invitation to Saniona Q3 investor call on 27 November 2025

Press release11/19/2025, 7:16 AM

BioStock: Video from Saniona's presentation at BioStock Life Science Summit 2025

Press release11/6/2025, 7:00 AM

Saniona AB’s Nomination Committee for the Annual General Meeting 2026

Press release9/25/2025, 7:59 AM

Redeye: Saniona - Optionality unlocked

Press release9/9/2025, 7:57 AM

BioStock: Saniona comments on their new chapter in epilepsy treatment

Regulatory press release9/4/2025, 6:00 AM

Saniona selects SAN2668 as first-in-class clinical candidate for paediatric epilepsy

Regulatory press release8/28/2025, 6:00 AM

Saniona publishes its interim report for the second quarter of 2025

Press release8/22/2025, 3:30 PM

Invitation to Saniona Q2 investor call on 28 August 2025

Press release8/20/2025, 2:08 PM

BioStock: Saniona’s CEO comments on the billion dollar deal

Regulatory press release8/20/2025, 11:30 AM

Saniona Enters Exclusive Licensing Agreement with Jazz Pharmaceuticals to Develop and Commercialize SAN2355

Press release8/12/2025, 6:00 AM

Saniona to present at several conferences in the second half of 2025

Regulatory press release7/31/2025, 6:00 AM

Change in number of shares and votes in Saniona AB

Regulatory press release6/26/2025, 3:30 PM

Fenja Capital II A/S requests conversion of the remaining outstanding convertibles for a total nominal amount of SEK 6 million

Press release6/25/2025, 12:30 PM

Saniona highlights Acadia Pharmaceuticals’ upcoming R&D Day

Press release6/19/2025, 6:00 AM

Saniona acquires headquarters to secure long-term stability

Press release6/4/2025, 10:09 AM

BioStock: Saniona’s CFO outlines clinical milestone strategy

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.